Amgen Inc. $AMGN Shares Bought by MCF Advisors LLC

MCF Advisors LLC boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 31.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 7,044 shares of the medical research company’s stock after purchasing an additional 1,671 shares during the period. MCF Advisors LLC’s holdings in Amgen were worth $1,988,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Laurel Wealth Advisors LLC increased its position in shares of Amgen by 27,765.8% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock valued at $1,870,880,000 after acquiring an additional 6,676,575 shares during the period. Norges Bank acquired a new position in shares of Amgen in the second quarter valued at about $1,663,726,000. Vanguard Group Inc. increased its holdings in shares of Amgen by 1.6% in the second quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock valued at $14,996,807,000 after purchasing an additional 841,117 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Amgen by 5.6% in the second quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock worth $3,600,043,000 after purchasing an additional 687,735 shares during the last quarter. Finally, Mizuho Markets Cayman LP acquired a new stake in shares of Amgen during the second quarter worth about $135,597,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Argus raised its price target to $400 and reiterated a Buy rating, signaling analyst confidence in Amgen’s outlook and providing fresh positive momentum for the stock. Read More.
• Positive Sentiment: Q4 results beat Street estimates and management’s commentary pushed the shares to a new 12‑month high — the earnings beat and upgraded FY‑2026 guidance underpin the rally. Read More.
• Positive Sentiment: Clinical progress: Amgen advanced xaluritamig into a first‑in‑human Phase 1b trial for hard‑to‑treat Ewing sarcoma — a development that adds long‑term pipeline upside if the program shows activity. Read More.
• Positive Sentiment: Post‑marketing safety study for IMLYGIC in melanoma reached completion — reduces an uncertainty from the label/safety perspective and may support that asset’s commercial outlook. Read More.
• Neutral Sentiment: Guggenheim raised its price target to $347 but kept a Neutral rating; the new PT still implies downside versus the current price, creating mixed signals for investors. Read More.
• Neutral Sentiment: Deutsche Bank moved its target to $295 and maintained a Hold — another measured call that tempers the enthusiasm from Buy-rated upgrades. Read More.
• Neutral Sentiment: Market commentary notes rotation into defensive/health names and institutional buying as contributors to the stock’s move to multi‑month highs — a broader-market technical tailwind rather than company‑specific news. Read More.
• Negative Sentiment: CVS said it will replace Amgen’s and Lilly’s bone‑disease treatments with lower‑cost alternatives on some preferred drug lists starting April 1 — a material commercial headwind for the affected product sales. Read More.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the sale, the senior vice president directly owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Rachna Khosla sold 890 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the transaction, the senior vice president directly owned 7,082 shares of the company’s stock, valued at $2,381,251.68. The trade was a 11.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 10,908 shares of company stock worth $3,674,966 over the last three months. Insiders own 0.76% of the company’s stock.

Amgen Price Performance

NASDAQ:AMGN opened at $384.20 on Friday. Amgen Inc. has a one year low of $261.43 and a one year high of $385.12. The stock has a market cap of $206.88 billion, a PE ratio of 27.00, a P/E/G ratio of 3.90 and a beta of 0.46. The stock has a 50 day moving average price of $334.45 and a 200 day moving average price of $311.49. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.99 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business’s revenue was up 8.6% compared to the same quarter last year. During the same quarter last year, the firm earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.6%. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s payout ratio is 66.90%.

Analysts Set New Price Targets

AMGN has been the subject of a number of recent research reports. Citigroup raised their price target on shares of Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a research report on Wednesday. The Goldman Sachs Group increased their price objective on shares of Amgen from $403.00 to $415.00 and gave the stock a “buy” rating in a research note on Wednesday. Scotiabank started coverage on shares of Amgen in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 target price for the company. BMO Capital Markets upped their price target on shares of Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. Finally, Wall Street Zen lowered Amgen from a “strong-buy” rating to a “buy” rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $351.65.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.